Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
South Asian Journal of Cancer · 01.10.2024 · 13 (04) · 296-299
DOI: 10.1055/s-0045-1804535 ↗Kurz gefasst
Fachartikel in der Zeitschrift South Asian Journal of Cancer, erschienen am 01.10.2024. Verfasst von Arvind Vaidyanathan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, Maharashtra, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Generic versions of bevacizumab are commonly used in India in patients with advanced/metastatic colorectal cancers (mCRCs), but there is limited real-world evidence (RWE) about their efficacy in comparison to the innovator bevacizumab. Patients diagnosed with mCRC between January 2017 and January 2022 and receiving a combination of chemotherapy and bevacizumab were retrospectively analyzed for demographic variables and survivals. The primary endpoint of the study was the estimation and comparison of median progression-free survival (mPFS) between patients receiving innovator versus generic bevacizumab as first-line therapy (CT1) by the Kaplan–Meier method. A total of 944 patients were included in the analysis, of whom 652 patients (69%) received bevacizumab as CT1, 449 patients (48%) during second-line chemotherapy (CT2), and 74 patients (8%) during third-line therapy (CT3). The innovator was administered to 132 patients (14%), while the remaining 812 patients (86%) received a generic molecule. With a median follow-up of 18 months, there was no difference in mPFS between patients receiving the innovator or biosimilar (10 vs. 9.3 months, p = 0.62). Similarly, there was no difference in median overall survival (mOS) between patients receiving the innovator or biosimilar during CT1 (17.8 vs. 18 months, p = 0.85). Among the patients who received bevacizumab during CT2, there was no statistically significant difference in mPFS between the innovator and the biosimilar (5.5 vs. 5.8 months, p = 0.97), nor was there a difference in mOS between patients receiving the innovator or biosimilar during CT2 (8.15 vs. 8.58 months, p = 0.16). The current study offers RWE to suggest similar outcomes with innovator and generic bevacizumab when combined with chemotherapy in mCRCs. This has significant implications in India and other low- and middle-income countries besides providing oncologists with greater confidence to use these molecules in their clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Dr. E Borges Road, Parel, Mumbai, Maharashtra, India.
ORCID-Profile: Arvind Vaidyanathan, Prabhat Bhargava, Vikas Ostwal
Zitieren
APA
Vaidyanathan, A., Vana, P., Joshi, N., Sourav, B., Bhargava, P., John, G., Ramaswamy, A., & Ostwal, V. (2024). Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers. South Asian Journal of Cancer, 13(04), 296-299. https://doi.org/10.1055/s-0045-1804535
Vancouver
Vaidyanathan A, Vana P, Joshi N, Sourav B, Bhargava P, John G, et al. Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers. South Asian Journal of Cancer. 2024;13(04):296-299. doi:10.1055/s-0045-1804535
BibTeX
@article{Vaidyanathan2024,
author = {Vaidyanathan, Arvind and Vana, Pranaya and Joshi, Nachiket and Sourav, Bikash and Bhargava, Prabhat and John, George and Ramaswamy, Anant and Ostwal, Vikas},
title = {Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers},
journal = {South Asian Journal of Cancer},
year = {2024},
volume = {13},
number = {04},
pages = {296--299},
doi = {10.1055/s-0045-1804535}
}
EUVIMED